American Tinnitus Association Announces New Board Leadership
June 25, 2019 09:15 ET
|
American Tinnitus Association
Vienna, Virginia, June 25, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) Board of Directors has elected Dr. Jill Meltzer as Chair and John Minnebo as Vice-Chair for two-year...
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
June 12, 2019 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
May is Mental Health Awareness Month: American Tinnitus Association Highlights Using Cognitive Behavioral Therapy to Manage Tinnitus
May 29, 2019 12:51 ET
|
American Tinnitus Association
Vienna, Virginia, May 29, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) has released a Conversations in Tinnitus “CBT to Reclaim Your Life,” podcast with Bruce Hubbard, PhD, to...
May is Mental Health Awareness Month: American Tinnitus Association Highlights Using Cognitive Behavioral Therapy to Manage Tinnitus
May 29, 2019 09:35 ET
|
American Tinnitus Association
Vienna, Virginia, May 29, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) has released a Conversations in Tinnitus “CBT to Reclaim Your Life,” podcast with Bruce Hubbard, PhD, to...
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
May 01, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
April 29, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
April 11, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Two Upcoming Investor Conferences
March 05, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 04, 2019 16:18 ET
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
February 25, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...